DPI (Dry powder inhaler) is a medical device used to deliver medicinal dry powder to lungs through inhalation. It is mainly used in the treatment of chronic respiratory diseases like bronchitis, asthma, COPD (Chronic Obstructive Pulmonary Disease), emphysema and other forms of bronchiectasis. Rather than intake of solid medicines (tablets and capsules), inhaled medicines has proven to be more efficient and work faster as dry inhale powder helps to breathe medicine to lungs effectually.
According to the report by Future Market Insights, the global dry powder inhaler market is expected to register a moderate CAGR of 4.0% during the forecast period 2017 – 2027. The global sale of dry powder inhaler is estimated to reach 4,000,000 Mn Units by the end of forecast period.
What are the market dynamics to boost the demand for dry powder inhaler?
- Initiatives taken by government to encourage adoption of dry powder inhaler
- Increasing consumer preference for single use dry powder inhaler
- Strong focus to offer diversified product portfolio by dry powder inhaler manufacturers
- Changing lifestyle habits coupled with the increasing air pollution level
- Increasing geriatric population suffering from respiratory diseases
Based on abovementioned factors, several healthcare professionals are highly likely to encourage patients to use dry powder inhalers during the forecast period. However, manufactures face challenges to cope with drawbacks in designing. For instance, less resistance to moisture may affect the functionality of dry powder inhaler. In addition, presence of alternatives like electric pumps and nebulizers is expected to hinder dry powder inhaler market growth avenues in the near future.
Where can market players find potential opportunities for strategic market expansion?
The presence of advanced healthcare infrastructure in North America together with the integration of innovative technologies in medical practice is expected to have positive impact on dry powder inhaler market. With the rising number of patients suffering from respiratory disorders, the demand for dry powder inhaler is expected to rise during the forecast period. Manufacturers are spending heavily to modify existing standard dry powder inhalers in order to provide diversified product portfolio and attract large customer base. Stringent guidelines enforced by regional government associated with chronic respiratory disorders therapeutics coupled with the increasing heavy investment to develop healthcare and pharmaceutical sector is expected to propel demand for dry powder inhalers during the forecast period.
Which application plays significant role to proliferate dry powder inhaler market growth?
A report by WHO (World health Organization), around 300 million people were recorded who suffering from asthma and nearly 240 million people from COPD. As dry powder inhalers have delivered efficient performance for treatment of such diseases, half of the patients prefer to use it. Hospital pharmacies are expected to remain prominent value share holder in dry powder inhaler market. This is attributed to direct interaction among practitioner, patients and vendor.
Growing prevalence of COPD (Chronic Obstructive Pulmonary Disorder) and asthma has been observed around the world, particularly in emerging economies. Increasing pollution level coupled with the increasing nicotine consumption are the primary factors for spreading of such diseases. As expensive therapies are not affordable by everyone, demand for cost-effective devices like dry powder inhaler are expected to rise in the near future. Single use dry powder inhalers are likely to remain higher in demand than multi-use ones for its easy handling and exact dosage delivery of medicines.
Who are the key manufacturers?
Several manufacturers like Novartis AG, Cipla Ltd., GlaxoSmithKline Plc, Chiesi Farmaceutici S.p.A., Vectura Group Plc. 3M Company, Astrazeneca Plc., MannKind Corporation and Boehringer Ingelheim GmbH are among other operating in prefilled syringe drug molecule market.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-666